Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Patrys provides update on development programme for anti-cancer product, PAT-LM1

Patrys Limited, a clinical stage biotechnology company, is pleased to provide an update on the development programme for anti-cancer product, PAT-LM1.

24 Mar 2014

Research reveals 2 key mechanisms of oxidative stress regulation

Regulation of oxidative stress is critical to cell survival. New preclinical research from Roswell Park Cancer Institute (RPCI) has revealed two key mechanisms by which oxidative stress is regulated in normal and cancerous cells.

7 Mar 2014

Safeguard Scientifics reports net income of $24 million for fourth quarter 2013

Safeguard Scientifics, Inc. today announced fourth quarter and full-year 2013 financial results. For the three months ended December 31, 2013, Safeguard's net income was $24.0 million, or $1.10 per share, compared to net loss of $10.8 million, or $0.51 per share for the same period in 2012. For the year ended December 31, 2013, Safeguard's net loss was $35.5 million, or $1.66 per share, compared to $39.4 million, or $1.88 per share for the same period in 2012.

6 Mar 2014

Triphase's marizomib receives FDA orphan drug designation for treatment of multiple myeloma

Triphase Accelerator Corporation today announced that marizomib, its novel, potent proteasome inhibitor, has been granted orphan drug designation by the U.S. Food and Drug Administration's Office of Orphan Products Development for the treatment of multiple myeloma. The orphan drug designation will provide Triphase with 7-year marketing exclusivity for marizomib and other benefits upon FDA approval.

28 Feb 2014

Protein M: an interview with Rajesh Grover, PhD, senior staff scientist, Lerner laboratory, TSRI

Protein M is a cell surface protein from Mycoplasma Genitalium that binds to all human antibodies.

26 Feb 2014

Study: Blacks are more likely to have precursor condition than whites

Blacks may be twice as likely as whites to develop multiple myeloma because they are more likely to have a precursor condition known as monoclonal gammopathy of undetermined significance (MGUS), a Mayo Clinic study has found.

25 Feb 2014

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Pharmacyclics, Inc. today reported financial results and recent developments for the quarter and year ended December 31, 2013.

20 Feb 2014

Experimental drug dinaciclib may improve myeloid leukemia, myeloma therapies

A pre-clinical study led by Virginia Commonwealth University Massey Cancer Center and Department of Internal Medicine researchers suggests that an experimental drug known as dinaciclib could improve the effectiveness of certain multiple myeloma and myeloid leukemia therapies.

19 Feb 2014

New research points to potential target for treating triple negative breast cancer

New research from the University of Michigan Comprehensive Cancer Center and Georgia Regents University finds that a protein that fuels an inflammatory pathway does not turn off in breast cancer, resulting in an increase in cancer stem cells. This provides a potential target for treating triple negative breast cancer, the most aggressive form of the disease.

17 Feb 2014

Congressmen to receive Edwin C. Whitehead award at Advocacy Awards Dinner

Reps. Frank Wolf (R-VA) and Chaka Fattah (D-PA) will receive the Edwin C. Whitehead Award for Medical Research Advocacy for their leadership and unwavering commitment to supporting policies that promote federal and private sector medical research and innovation.

13 Feb 2014

IMF announces approval of POMALYST medication in Canada for patients with myeloma

The International Myeloma Foundation - improving the quality of life of myeloma patients while working toward prevention and a cure - said POMALYST (pomalidomide) approval by Health Canada provides patients the most up-to-date oral therapy available for patients who have exhausted all other treatments.

11 Feb 2014

Ligand Pharmaceuticals' total revenues for Q4 2013 increase 8% to $14.7 million

Ligand Pharmaceuticals Incorporated today reported financial results for the three and 12 months ended December 31, 2013, and provided an operating forecast and program updates.

11 Feb 2014

TSRI scientists discover unusual protein that probably helps some bacteria evade immune response

A team led by scientists at The Scripps Research Institute (TSRI) has discovered an unusual bacterial protein that attaches to virtually any antibody and prevents it from binding to its target. Protein M, as it is called, probably helps some bacteria evade the immune response and establish long-term infections.

7 Feb 2014

FDA grants Breakthrough Therapy designation to GSK's Promacta/Revolade for treatment of cytopenias

Ligand Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration has granted its partner GlaxoSmithKline plc Breakthrough Therapy designation for Promacta/Revolade (eltrombopag) for the treatment of cytopenias in patients with severe aplastic anemia (SAA) who have had insufficient response to immunosuppressive therapy.

3 Feb 2014

Allogeneic transplants via Blood/Marrow Transplant Program show better outcomes

For the fourth consecutive year, outcomes for patients receiving allogeneic transplants through the Blood and Marrow Transplant Program at Roswell Park Cancer Institute (RPCI) have been shown to be significantly better than would be expected among the patient population treated.

29 Jan 2014

BioLineRx's BL-8040 gets FDA Orphan Drug Designation for stem cell mobilization treatment

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has received notice from the U.S. Food & Drug Administration confirming an Orphan Drug Designation of BL-8040 as a treatment for stem cell mobilization, in addition to the Orphan Drug Designation previously granted to BL-8040 as a treatment for Acute Myeloid Leukemia.

23 Jan 2014

BMH-21 chemical compound has ability to shut down a common cancer process

Johns Hopkins scientists say a previously known but little studied chemical compound targets and shuts down a common cancer process. In studies of laboratory-grown human tumor cell lines, the drug disrupted tumor cell division and prevented growth of advanced cancer cells.

15 Jan 2014

Smoking, diets rich in animal products, alcohol have correlations with cancer incidence rates, says study

A multicountry study just published in Nutrients finds that smoking, diets rich in animal products, and alcohol have the strongest correlations with cancer incidence rates. The cancer incidence rates are from 2008 as assembled by the International Agency for Research on Cancer of the World Health Organization.

28 Dec 2013

Epsilon inks multi-year renewal, expansion agreements with The Leukemia & Lymphoma Society

Epsilon, an Alliance Data company, has signed multi-year renewal and expansion agreements with The Leukemia & Lymphoma Society the world's largest voluntary health agency dedicated to finding cures for blood cancers. Epsilon has partnered with the LLS since the early 1990s, providing marketing services geared toward engaging LLS constituents across a range of fundraising and donor programs such as Light the Night, Team In Training and Man & Women of the Year.

17 Dec 2013

BioLineRx reports promising initial results from Phase 2 trial of BL-8040 in AML patients

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today promising initial results for its BL-8040 drug candidate in a Phase 2 clinical trial for patients with relapsed or refractory acute myeloid leukemia (AML).

16 Dec 2013

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Patrys provides update on development programme for anti-cancer product, PAT-LM1

Research reveals 2 key mechanisms of oxidative stress regulation

Safeguard Scientifics reports net income of $24 million for fourth quarter 2013

Triphase's marizomib receives FDA orphan drug designation for treatment of multiple myeloma

Protein M: an interview with Rajesh Grover, PhD, senior staff scientist, Lerner laboratory, TSRI

Study: Blacks are more likely to have precursor condition than whites

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Experimental drug dinaciclib may improve myeloid leukemia, myeloma therapies

New research points to potential target for treating triple negative breast cancer

Congressmen to receive Edwin C. Whitehead award at Advocacy Awards Dinner

IMF announces approval of POMALYST medication in Canada for patients with myeloma

Ligand Pharmaceuticals' total revenues for Q4 2013 increase 8% to $14.7 million

TSRI scientists discover unusual protein that probably helps some bacteria evade immune response

FDA grants Breakthrough Therapy designation to GSK's Promacta/Revolade for treatment of cytopenias

Allogeneic transplants via Blood/Marrow Transplant Program show better outcomes

BioLineRx's BL-8040 gets FDA Orphan Drug Designation for stem cell mobilization treatment

BMH-21 chemical compound has ability to shut down a common cancer process

Smoking, diets rich in animal products, alcohol have correlations with cancer incidence rates, says study

Epsilon inks multi-year renewal, expansion agreements with The Leukemia & Lymphoma Society

BioLineRx reports promising initial results from Phase 2 trial of BL-8040 in AML patients

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in